# A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

> **NCT06887933** · PHASE4 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 67 (estimated)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Niraparib

## Key facts

- **NCT ID:** NCT06887933
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-07-08
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887933, "A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06887933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*